A Study of Zanubrutinib in Patients With ITP

Summary

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Zanubrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

Timeline

Start

2022-01-01

Primary completion

2022-10-30

Completion

2022-10-30

Publications

• Huang QS, Fu HX, Wang CC, Zhu XL, He Y, Wu J, Chen Q, Zhao P, An ZY, Liu KY, Huang XJ, Zhang XH. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia. Am J Hematol. 2025 Aug;100(8):1314-1322. doi: 10.1002/ajh.27718. Epub 2025 May 20.

Drugs

Indications